The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes
- 17 October 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Thrombosis and Thrombolysis
- Vol. 41 (2), 273-278
- https://doi.org/10.1007/s11239-015-1286-3
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Idarucizumab for Dabigatran ReversalThe New England Journal of Medicine, 2015
- Nonclinical Safety Assessment of PER977International Journal of Toxicology, 2015
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) InhibitorsBlood, 2014
- Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired SubjectsBlood, 2014
- Late-Breaking Clinical Trial AbstractsCirculation, 2014
- Use of PER977 to Reverse the Anticoagulant Effect of EdoxabanThe New England Journal of Medicine, 2014
- Reversal Agents in Development for the New Oral AnticoagulantsPostgraduate Medicine, 2014
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa InhibitorsBlood, 2013
- A specific antidote for dabigatran: functional and structural characterizationBlood, 2013
- A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor XaNature Medicine, 2013